Haemonetics Gross Profit from 2010 to 2024

HAE Stock

USD 91.78 1.60 1.71%

Haemonetics' Gross Profit is increasing over the years with slightly volatile fluctuation. Overall, Gross Profit is expected to go to about 710.4 M this year. Gross Profit is the profit Haemonetics makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. View All Fundamentals

Gross Profit

First Reported

1990-06-30

Previous Quarter

166.8 M

Current Value

187.4 M

Quarterly Volatility

40.1 M

Oil Shock

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check Haemonetics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Haemonetics' main balance sheet or income statement drivers, such as Interest Expense of 15.4 M, Total Revenue of 1.4 B or Gross Profit of 710.4 M, as well as many indicators such as Price To Sales Ratio of 4.27, Dividend Yield of 0.0098 or PTB Ratio of 5.13. Haemonetics financial statements analysis is a perfect complement when working with Haemonetics Valuation or Volatility modules.

Check out the analysis of Haemonetics Correlation against competitors.

For information on how to trade Haemonetics Stock refer to our How to Trade Haemonetics Stock guide.

Latest Haemonetics' Gross Profit Growth Pattern

Below is the plot of the Gross Profit of Haemonetics over the last few years. Gross profit is a required income statement account that reflects total revenue of Haemonetics minus its cost of goods sold. It is profit before Haemonetics operating expenses, interest payments and taxes. Gross profit is also known as gross margin. It is the profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. Haemonetics' Gross Profit historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Haemonetics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 530.77 M

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Gross Profit

Timeline

Haemonetics Gross Profit Regression Statistics

	Arithmetic Mean	457,407,723
	Geometric Mean	435,545,321
	Coefficient Of Variation	29.53
	Mean Deviation	95,457,535
	Median	428,131,000
	Standard Deviation	135,053,891
	Sample Variance	18239.6T
	Range	553.1M
	R-Value	0.81
	Mean Square Error	6619T
	R-Squared	0.66
	Significance	0.0002
	Slope	24,589,961
	Total Sum of Squares	255353.7T

Haemonetics Gross Profit History

	2024	710.4 M
	2023	676.5 M
	2022	615.1 M
	2021	505.5 M
	2020	397.8 M
	2019	484.5 M
	2018	417.5 M

Other Fundumenentals of Haemonetics

Gross Profit Margin

Haemonetics Gross Profit component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Short Term Investments	Common Stock	Long Term Debt	Good Will	Property Plant Equipment	Current Deferred Revenue	Net Tangible Assets	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Accumulated Depreciation	Short Long Term Debt	Cash And Equivalents	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.64	0.87	0.3	0.91	0.6	0.96	0.74	0.1	0.95	-0.57	0.53	0.91	0.97	0.53	0.28	-0.83	0.92	0.74	0.59	-0.33	-0.56	0.69	0.19	0.68	-0.45
Total Stockholder Equity	0.64		0.29	0.67	0.61	0.87	0.46	0.87	0.11	0.54	-0.85	0.59	0.39	0.53	0.77	-0.05	-0.38	0.39	0.45	0.4	-0.55	-0.28	0.36	0.21	0.19	0.23
Net Debt	0.87	0.29		-0.01	0.72	0.33	0.95	0.49	0.04	0.9	-0.17	0.49	0.96	0.93	0.35	0.58	-0.9	0.96	0.73	0.6	-0.1	-0.58	0.71	0.22	0.73	-0.48
Retained Earnings	0.3	0.67	-0.01		0.23	0.41	0.06	0.3	-0.18	0.34	-0.54	0.11	0.1	0.25	0.3	-0.37	0.04	0.12	-0.23	0.3	-0.17	0.19	-0.03	0.32	-0.33	0.01
Accounts Payable	0.91	0.61	0.72	0.23		0.71	0.84	0.7	0.17	0.76	-0.6	0.54	0.74	0.82	0.6	0.27	-0.62	0.77	0.74	0.34	-0.35	-0.55	0.64	0.28	0.66	-0.45
Net Receivables	0.6	0.87	0.33	0.41	0.71		0.48	0.85	0.13	0.42	-0.78	0.66	0.39	0.46	0.81	0.14	-0.33	0.4	0.57	0.21	-0.56	-0.38	0.4	0.29	0.33	0.19
Total Liab	0.96	0.46	0.95	0.06	0.84	0.48		0.68	0.1	0.93	-0.37	0.51	0.96	0.98	0.42	0.43	-0.92	0.96	0.8	0.63	-0.24	-0.59	0.76	0.12	0.8	-0.45
Total Current Assets	0.74	0.87	0.49	0.3	0.7	0.85	0.68		0.19	0.61	-0.72	0.61	0.58	0.66	0.65	0.12	-0.65	0.58	0.7	0.51	-0.56	-0.37	0.57	0.02	0.54	0.19
Short Term Debt	0.1	0.11	0.04	-0.18	0.17	0.13	0.1	0.19		0.01	-0.2	0.35	-0.14	0.05	0.19	0.27	-0.12	-0.14	0.24	-0.41	-0.35	0.01	0.15	-0.21	-0.12	0.09
Intangible Assets	0.95	0.54	0.9	0.34	0.76	0.42	0.93	0.61	0.01		-0.42	0.45	0.91	0.98	0.38	0.29	-0.87	0.93	0.61	0.7	-0.19	-0.43	0.63	0.22	0.59	-0.46
Short Term Investments	-0.57	-0.85	-0.17	-0.54	-0.6	-0.78	-0.37	-0.72	-0.2	-0.42		-0.54	-0.25	-0.4	-0.69	0.17	0.27	-0.27	-0.34	-0.09	0.75	0.35	-0.07	0.04	-0.08	0.0
Common Stock	0.53	0.59	0.49	0.11	0.54	0.66	0.51	0.61	0.35	0.45	-0.54		0.43	0.46	0.85	0.71	-0.53	0.42	0.58	0.12	-0.75	-0.52	0.21	-0.02	0.22	0.17
Long Term Debt	0.91	0.39	0.96	0.1	0.74	0.39	0.96	0.58	-0.14	0.91	-0.25	0.43		0.95	0.35	0.43	-0.9	1.0	0.69	0.74	-0.13	-0.55	0.71	0.15	0.79	-0.45
Good Will	0.97	0.53	0.93	0.25	0.82	0.46	0.98	0.66	0.05	0.98	-0.4	0.46	0.95		0.41	0.34	-0.89	0.96	0.7	0.69	-0.2	-0.5	0.73	0.18	0.69	-0.47
Property Plant Equipment	0.53	0.77	0.35	0.3	0.6	0.81	0.42	0.65	0.19	0.38	-0.69	0.85	0.35	0.41		0.41	-0.32	0.35	0.61	0.12	-0.63	-0.65	0.3	0.21	0.23	0.21
Current Deferred Revenue	0.28	-0.05	0.58	-0.37	0.27	0.14	0.43	0.12	0.27	0.29	0.17	0.71	0.43	0.34	0.41		-0.49	0.41	0.49	0.07	-0.23	-0.43	0.29	0.02	0.31	-0.01
Net Tangible Assets	-0.83	-0.38	-0.9	0.04	-0.62	-0.33	-0.92	-0.65	-0.12	-0.87	0.27	-0.53	-0.9	-0.89	-0.32	-0.49		-0.89	-0.71	-0.7	0.3	0.46	-0.63	0.1	-0.71	0.26
Long Term Debt Total	0.92	0.39	0.96	0.12	0.77	0.4	0.96	0.58	-0.14	0.93	-0.27	0.42	1.0	0.96	0.35	0.41	-0.89		0.7	0.72	-0.11	-0.56	0.72	0.2	0.78	-0.49
Capital Surpluse	0.74	0.45	0.73	-0.23	0.74	0.57	0.8	0.7	0.24	0.61	-0.34	0.58	0.69	0.7	0.61	0.49	-0.71	0.7		0.35	-0.25	-0.76	0.77	0.19	0.84	-0.11
Deferred Long Term Liab	0.59	0.4	0.6	0.3	0.34	0.21	0.63	0.51	-0.41	0.7	-0.09	0.12	0.74	0.69	0.12	0.07	-0.7	0.72	0.35		0.08	-0.16	0.55	0.11	0.54	-0.03
Accumulated Depreciation	-0.33	-0.55	-0.1	-0.17	-0.35	-0.56	-0.24	-0.56	-0.35	-0.19	0.75	-0.75	-0.13	-0.2	-0.63	-0.23	0.3	-0.11	-0.25	0.08		0.31	0.16	0.51	0.01	-0.17
Short Long Term Debt	-0.56	-0.28	-0.58	0.19	-0.55	-0.38	-0.59	-0.37	0.01	-0.43	0.35	-0.52	-0.55	-0.5	-0.65	-0.43	0.46	-0.56	-0.76	-0.16	0.31		-0.42	-0.1	-0.61	0.26
Cash And Equivalents	0.69	0.36	0.71	-0.03	0.64	0.4	0.76	0.57	0.15	0.63	-0.07	0.21	0.71	0.73	0.3	0.29	-0.63	0.72	0.77	0.55	0.16	-0.42		0.34	0.79	-0.16
Net Invested Capital	0.19	0.21	0.22	0.32	0.28	0.29	0.12	0.02	-0.21	0.22	0.04	-0.02	0.15	0.18	0.21	0.02	0.1	0.2	0.19	0.11	0.51	-0.1	0.34		0.09	-0.1
Net Working Capital	0.68	0.19	0.73	-0.33	0.66	0.33	0.8	0.54	-0.12	0.59	-0.08	0.22	0.79	0.69	0.23	0.31	-0.71	0.78	0.84	0.54	0.01	-0.61	0.79	0.09		-0.31
Capital Stock	-0.45	0.23	-0.48	0.01	-0.45	0.19	-0.45	0.19	0.09	-0.46	0.0	0.17	-0.45	-0.47	0.21	-0.01	0.26	-0.49	-0.11	-0.03	-0.17	0.26	-0.16	-0.1	-0.31

Click cells to compare fundamentals

About Haemonetics Financial Statements

Haemonetics stakeholders use historical fundamental indicators, such as Haemonetics' Gross Profit, to determine how well the company is positioned to perform in the future. Although Haemonetics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Haemonetics' assets and liabilities are reflected in the revenues and expenses on Haemonetics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Haemonetics. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Gross Profit	676.5 M	710.4 M
Gross Profit Margin	0.52	0.46

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

F	Ford Motor
GM	General Motors
MSFT	Microsoft

When determining whether Haemonetics is a strong investment it is important to analyze Haemonetics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Haemonetics' future performance. For an informed investment choice regarding Haemonetics Stock, refer to the following important reports:

How To Invest In Haemonetics

Details

Is Haemonetics Stock a good investment?

Details

What is Haemonetics' Net Worth?

Details

Largest Health Care Equipment & Supplies Companies

View

Largest Health Care Equipment & Services Companies

View

Check out the analysis of Haemonetics Correlation against competitors.

For information on how to trade Haemonetics Stock refer to our How to Trade Haemonetics Stock guide.

You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Haemonetics. If investors know Haemonetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Haemonetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.375

Earnings Share

2.41

Revenue Per Share

26.77

Quarterly Revenue Growth

0.086

Return On Assets

0.0588

The market value of Haemonetics is measured differently than its book value, which is the value of Haemonetics that is recorded on the company's balance sheet. Investors also form their own opinion of Haemonetics' value that differs from its market value or its book value, called intrinsic value, which is Haemonetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Haemonetics' market value can be influenced by many factors that don't directly affect Haemonetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Haemonetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Haemonetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Haemonetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Haemonetics Gross Profit from 2010 to 2024

Latest Haemonetics' Gross Profit Growth Pattern

Haemonetics Gross Profit Regression Statistics

Haemonetics Gross Profit History

Other Fundumenentals of Haemonetics

Haemonetics Gross Profit component correlations

About Haemonetics Financial Statements

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY